PET imaging of cellular proliferation

David A. Mankoff, Anthony F. Shields, Kenneth Krohn

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

PET cellular proliferation imaging has its roots in a long history of in vitro cellular proliferation studies to characterize cancer and in the understanding of the biology of thymidine incorporation into DNA gained from these studies. PET imaging represents the logical translation of the in vitro work to measure in vivo tumor proliferation. Preclinical studies of [ 11C]-thymidine and other PET-labeled thymidine analogues set the stage for early clinical studies that provided very promising results. Recent progress in the application of [18F]-FLT, a clinically practical PET thymidine analogue, to patient studies sets the next stage for clinical PET cellular proliferation imaging. Further mechanistic studies of the imaging agents and well-designed clinical trials will be important in moving PET proliferation imaging into what is likely to be a significant role in the care of cancer patients by providing a quantitative measure of tumor response to cytotoxic or cytostatic therapy.

Original languageEnglish (US)
Pages (from-to)153-167
Number of pages15
JournalRadiologic Clinics of North America
Volume43
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Thymidine
Cell Proliferation
Neoplasms
Cytostatic Agents
Patient Care
Clinical Trials
DNA
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

PET imaging of cellular proliferation. / Mankoff, David A.; Shields, Anthony F.; Krohn, Kenneth.

In: Radiologic Clinics of North America, Vol. 43, No. 1, 01.2005, p. 153-167.

Research output: Contribution to journalArticle

Mankoff, David A. ; Shields, Anthony F. ; Krohn, Kenneth. / PET imaging of cellular proliferation. In: Radiologic Clinics of North America. 2005 ; Vol. 43, No. 1. pp. 153-167.
@article{b18e1170ecc24263b2371ad6b9195d62,
title = "PET imaging of cellular proliferation",
abstract = "PET cellular proliferation imaging has its roots in a long history of in vitro cellular proliferation studies to characterize cancer and in the understanding of the biology of thymidine incorporation into DNA gained from these studies. PET imaging represents the logical translation of the in vitro work to measure in vivo tumor proliferation. Preclinical studies of [ 11C]-thymidine and other PET-labeled thymidine analogues set the stage for early clinical studies that provided very promising results. Recent progress in the application of [18F]-FLT, a clinically practical PET thymidine analogue, to patient studies sets the next stage for clinical PET cellular proliferation imaging. Further mechanistic studies of the imaging agents and well-designed clinical trials will be important in moving PET proliferation imaging into what is likely to be a significant role in the care of cancer patients by providing a quantitative measure of tumor response to cytotoxic or cytostatic therapy.",
author = "Mankoff, {David A.} and Shields, {Anthony F.} and Kenneth Krohn",
year = "2005",
month = "1",
doi = "10.1016/j.rcl.2004.09.005",
language = "English (US)",
volume = "43",
pages = "153--167",
journal = "Radiologic Clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - PET imaging of cellular proliferation

AU - Mankoff, David A.

AU - Shields, Anthony F.

AU - Krohn, Kenneth

PY - 2005/1

Y1 - 2005/1

N2 - PET cellular proliferation imaging has its roots in a long history of in vitro cellular proliferation studies to characterize cancer and in the understanding of the biology of thymidine incorporation into DNA gained from these studies. PET imaging represents the logical translation of the in vitro work to measure in vivo tumor proliferation. Preclinical studies of [ 11C]-thymidine and other PET-labeled thymidine analogues set the stage for early clinical studies that provided very promising results. Recent progress in the application of [18F]-FLT, a clinically practical PET thymidine analogue, to patient studies sets the next stage for clinical PET cellular proliferation imaging. Further mechanistic studies of the imaging agents and well-designed clinical trials will be important in moving PET proliferation imaging into what is likely to be a significant role in the care of cancer patients by providing a quantitative measure of tumor response to cytotoxic or cytostatic therapy.

AB - PET cellular proliferation imaging has its roots in a long history of in vitro cellular proliferation studies to characterize cancer and in the understanding of the biology of thymidine incorporation into DNA gained from these studies. PET imaging represents the logical translation of the in vitro work to measure in vivo tumor proliferation. Preclinical studies of [ 11C]-thymidine and other PET-labeled thymidine analogues set the stage for early clinical studies that provided very promising results. Recent progress in the application of [18F]-FLT, a clinically practical PET thymidine analogue, to patient studies sets the next stage for clinical PET cellular proliferation imaging. Further mechanistic studies of the imaging agents and well-designed clinical trials will be important in moving PET proliferation imaging into what is likely to be a significant role in the care of cancer patients by providing a quantitative measure of tumor response to cytotoxic or cytostatic therapy.

UR - http://www.scopus.com/inward/record.url?scp=13944284550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944284550&partnerID=8YFLogxK

U2 - 10.1016/j.rcl.2004.09.005

DO - 10.1016/j.rcl.2004.09.005

M3 - Article

C2 - 15693654

AN - SCOPUS:13944284550

VL - 43

SP - 153

EP - 167

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

SN - 0033-8389

IS - 1

ER -